Studies on drug–DNA complexes, adriamycin–d-(TGATCA)2 and 4′-epiadriamycin–d-(CGATCG)2, by phosphorus-31 nuclear magnetic resonance spectroscopy

✍ Scribed by Prashansa Agrawal; Girjesh Govil; Ritu Barthwal

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 411 KB
• Volume: 47
• Category: Article
• ISSN: 0749-1581
• DOI: 10.1002/mrc.2398

✦ Synopsis

Abstract

The complexes of adriamycin–d‐(TGATCA)~2~ and 4′‐epiadriamycin–d‐(CGATCG)~2~ are studied by one‐ and two‐dimensional ^31^P nuclear magnetic resonance spectroscopy (NMR) at 500 MHz in the temperature range 275–328 K and as a function of drug to DNA ratio (0.0–2.0). The binding of drug to DNA is clearly evident in ^31^P^31^P exchange NOESY spectra that shows two sets of resonances in slow chemical exchange. The phosphate resonances at the intercalating steps, T1pG2/C1pG2 and C5pA6/C5pG6, shift downfield up to 1.7 ppm and that at the adjacent step shift downfield up to 0.7 ppm, whereas the central phosphate A3pT4 is relatively unaffected. The variations of chemical shift with drug to DNA ratio and temperature as well as linewidths are different in each of the two complexes. These observations reflect change in population of B~I~/B~II~ conformation, stretching of backbone torsional angle ζ, and distortions in OPO bond angles that occur on binding of drug to DNA. To the best of our knowledge, there are no solution studies on 4′‐epiadriamycin, a better tolerated drug, and binding of daunomycin or its analogue to d‐(TGATCA)~2~ hexamer sequence. The studies report the use of ^31^P NMR as a tool to differentiate various complexes. The specific differences may well be the reasons that are responsible for different antitumor action of these drugs due to different binding ability and distortions in DNA. Copyright © 2009 John Wiley & Sons, Ltd.